McMurray, J., Ezekowitz, J. A, Lewis, B. S, Gersh, B. J, Van Diepen, S., Amerena, J., Bartunek, J., Commerford, P., Oh, B. H, Harjola, V., Al-Khatib, S. M, Hanna, M., Alexander, J. H, Lopes, R. D, Wojdyla, D. M, Wallentin, L. & Granger, CB. (2013). Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation : insights from the ARISTOTLE trial. Circulation: Heart Failure,6(3), 451-460. United States: Lippincott Williams & Wilkins. Retrieved from https://doi.org/10.1161/CIRCHEARTFAILURE.112.000143
We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin.
Mary MacKillop Institute for Health Research
Access may be restricted.